Nikhil Babu Oommen
Overview
Explore the profile of Nikhil Babu Oommen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olmos D, Brewer D, Clark J, Danila D, Parker C, Attard G, et al.
Lancet Oncol
. 2012 Oct;
13(11):1114-24.
PMID: 23059046
Background: Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients...
2.
Attard G, Reid A, Auchus R, Hughes B, Mulick Cassidy A, Thompson E, et al.
J Clin Endocrinol Metab
. 2011 Dec;
97(2):507-16.
PMID: 22170708
Context: Abiraterone acetate is a small-molecule cytochrome P450 17A1 (CYP17A1) inhibitor that is active in castration-resistant prostate cancer. Objective: Our objective was to determine the impact of abiraterone with and...
3.
Reid A, Attard G, Danila D, Oommen N, Olmos D, Fong P, et al.
J Clin Oncol
. 2010 Feb;
28(9):1489-95.
PMID: 20159823
Purpose: The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer...
4.
Attard G, Reid A, AHern R, Parker C, Oommen N, Folkerd E, et al.
J Clin Oncol
. 2009 May;
27(23):3742-8.
PMID: 19470933
Purpose: It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent. Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in...
5.
Attard G, Swennenhuis J, Olmos D, Reid A, Vickers E, AHern R, et al.
Cancer Res
. 2009 Apr;
69(7):2912-8.
PMID: 19339269
Hormone-driven expression of the ERG oncogene after fusion with TMPRSS2 occurs in 30% to 70% of therapy-naive prostate cancers. Its relevance in castration-resistant prostate cancer (CRPC) remains controversial as ERG...